Home> Press Release> Press Release (2019)> Accelerating Overseas Development of COP for Medical Use ~Presentation at the U.S. Food and Drug Administration (FDA) Technology Seminar~

Accelerating Overseas Development of COP for Medical Use
~Presentation at the U.S. Food and Drug Administration (FDA) Technology Seminar~
Print Page

July 12, 2019


PDF(338KB)

Zeon Corporation (president: Kimiaki Tanaka) explained the technology behind cyclo olefin polymers (COPs), used as a material for pre-filled syringes*1, during a presentation on May 10, 2019 at a technology seminar hosted by the U.S. Food and Drug Administration (FDA).


Zeon’s COPs (trade names: ZEONEX®, ZEONOR®) offer high transparency comparable to glass and excellent quality in terms of high purity, low water absorption, mechanical strength, and chemical stability, and they are already being widely used as materials for optical products. Due to their other features of extremely low adsorption and aggregation of proteins, COPs have drawn much attention for their potential use as packaging materials in the rapidly expanding field of biomedical products.
 
The seminar, hosted by the Office of Biotechnology Products (OBP) under the FDA, was held to educate FDA employees on medical technologies. OBP invited the Zeon to make a presentation during the scientific seminar.
 
The Zeon Group will continue with its proactive provision of solutions grounded in its unique technologies while contributing to the development of medicine.


*1:Syringes pre-filled with medication to eliminate the risk of infection and reduce errors when adjusting the volume of medication to be administered.

Adsorption Properties of ZEONEX
Pre-filled syringe made of COP Pre-filled syringe made of COP
mailFor further information
  • Zeon Corporation,
    Department of Corporate Communications
  • Tel: +81-3-3216-2747
Contact Form

  • Zeon Corporation, Specialty Plastics Division
  • Tel: +81-3-3216-1769
Home> Press Release> Press Release (2019)> Accelerating Overseas Development of COP for Medical Use ~Presentation at the U.S. Food and Drug Administration (FDA) Technology Seminar~
Page top